A Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed Slow-Growing Cancer of the Lymph Nodes (Indolent Lymphoma)
- Conditions
- Relapsed Indolent LymphomaMedDRA version: 14.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2010-023335-41-AT
- Lead Sponsor
- Abbott
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
1. Relapsed indolent b-cell lymphoma with ECOG performance status = 2
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 28
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 60
Exclusion Criteria
1. Diagnosis of grade 3b follicular lymphoma or transformed lymphoma
2. Refractory to bendamustine
3. Discontinued rituximab due to toxicity
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method